Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 10184Triple Negative Breast Neoplasms 1046Neoplasms 574Ovarian Neoplasms 564Neoplasm Metastasis 515Colorectal Neoplasms 473Carcinoma, Non-Small-Cell Lung 468Prostatic Neoplasms 440Lung Neoplasms 433Pancreatic Neoplasms 312Melanoma 299Stomach Neoplasms 295Breast Neoplasms, Male 257Motor Activity 252Colonic Neoplasms 238Uterine Cervical Neoplasms 227Endometrial Neoplasms 223Head and Neck Neoplasms 218Carcinoma, Intraductal, Noninfiltrating 217Carcinoma, Renal Cell 192Squamous Cell Carcinoma of Head and Neck 181Sarcoma 177Urinary Bladder Neoplasms 159Esophageal Neoplasms 155Brain Neoplasms 155Breast Carcinoma In Situ 154Lymphedema 148Fatigue 136Carcinoma, Ovarian Epithelial 134Small Cell Lung Carcinoma 130

Interventions

palbociclib 1copanlisib 1Radiotherapy 1Radiation 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Estrogen Receptor Positive × Breast × Clear all
NCT03359954 2026-03-05

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
25 enrolled
Breast

Estrogen Receptor Positive

NCT03377101 2018-08-14

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Breast

Estrogen Receptor Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡